Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Bridion Generic Vials Hit Market in Droves at 32% of Originator Price
June 14, 2024
- Choseido Contract Manufactured Cephem Antibiotics for 8 Firms
June 14, 2024
- GSK to Discontinue Immediate-Release Versions of Paxil in Japan
June 14, 2024
- Pfizer Has High Hopes for Elrexfio/Prevenar 20, Rich ADC Assets after Seagen Deal
June 13, 2024
- Lilly Set to Raise Profile as Only Eczema Player with Oral and Injectable Options
June 13, 2024
- Astellas’ Gastric Cancer Drug Vyloy Now Available in Japan
June 13, 2024
- Ono Completes Acquisition of Deciphera
June 13, 2024
- En Route to 2030 Target, Shionogi to Carve Out New Biz in Areas with High Medical Needs
June 12, 2024
- Otsuka Resolved to Log 2.5 Trillion Yen in FY2028 by Offsetting Patent Cliffs with Novel Drugs
June 12, 2024
- Kyowa Kirin to Build Biologics Manufacturing Site in North Carolina
June 12, 2024
- Maruho Launches Mitchga 30 mg Vial Version in Japan
June 12, 2024
- US FDA Snubs Mitsubishi Tanabe’s Parkinson’s Drug
June 12, 2024
- Takeda Rebuts ISS’ Advice to Vote against Re-Election of CEO Weber
June 11, 2024
- Susana Murteira Tapped as Amgen Japan President
June 11, 2024
- Alecensa Snags EU OK for Adjuvant Setting of ALK-Positive NSCLC
June 11, 2024
- Japan Ethical Drug Sales Up 7.3% in April: Crecon
June 11, 2024
- Keytruda Tops Japan Drug Sales Ranking for 8 Months on End: Encise
June 11, 2024
- Takeda Rolls Out Obizur for Acquired Hemophilia A in Japan
June 11, 2024
- Kissei Grants Korean Rights for GnRH Antagonist Linzagolix to JW
June 11, 2024
- Leqembi’s Monthly IV Dosing Accepted for FDA Review: Eisai
June 11, 2024
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…